Project report
Joint Publication of the First 2024-2025 National Influenza Annual Report by the Korea Disease Control and Prevention Agency and the National Health Insurance Service.
Boyeong Ryu, Jia Kim, Nam-Joo Lee, Minji Koo, Jeeyeon Shin et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This report analyzes influenza activity and disease burden during the 2024-2025 season in South Korea, using surveillance data, medical claims, and vaccination records from national health systems. The influenza season peaked at the highest level since 2016, with approximately 3.86 million cases identified and total medical costs reaching 629.5 billion KRW. Vaccination coverage was 70% among children aged 6 months to 13 years and 81.6% among adults aged 65 and older. The analysis showed that influenza vaccination prevented an estimated 143,868 cases and 3,506 deaths, with vaccine effectiveness against severe outcomes ranging from 63.7% to 74.6%.
Key points
- Influenza-like illness peaked at 99.8 cases per 1,000 outpatients in early 2025, the highest level since 2016
- Vaccination coverage was 70.0% among children aged 6 months to 13 years and 81.6% among adults aged 65 years and older
- Vaccine effectiveness against severe outcomes ranged from 63.7% to 74.6%, and against mortality ranged from 52.2% to 81.1% depending on age group
- Influenza vaccination prevented an estimated 143,868 cases and 3,506 deaths during the season
- Total medical costs reached 629.5 billion KRW, with hospitalization accounting for 77.3% of costs
Limitations
This report analyzes aggregate national data and does not provide detailed information about specific population subgroups beyond age categories, nor does it explain the reasons for increased medical costs despite declining case numbers. The report also does not discuss equity in vaccination access or outcomes across different demographic groups.
Abstract
OBJECTIVES: The first National Influenza Annual Report was jointly released by the Korea Disease Control and Prevention Agency (KDCA) and the National Health Insurance Service (NHIS) to provide a comprehensive analysis of influenza activity and the burden of disease during the 2024-2025 influenza season. METHODS: Influenza activity was analyzed using patient- and pathogen-based surveillance data, medical costs data, vaccination coverage, and vaccine effectiveness (VE) estimates. Data were obtained from the KDCA sentinel surveillance system, the National Immunization Program, and the NHIS national health information databases. VE was estimated using both a target trial emulation (TTE)-based retrospective cohort design to assess age-specific outcomes and an interrupted time series (ITS) method with dynamic cohort to evaluate time-varying protection. RESULTS: During the 2024-2025 season, influenza-like illness peaked at 99.8 cases per 1,000 outpatients in the first week of 2025, the highest level recorded since 2016. The overall influenza virus detection rate was 15.2%, with a winter wave dominated by influenza A and a spring wave of influenza B. NHIS claims identified approximately 3.86 million influenza cases, indicating a decline from the previous season. Despite this decrease in case numbers, total medical costs continued to increase in the post-coronavirus disease 2019 period, reaching 629.5 billion KRW, with hospitalization accounting for 77.3% of the total costs. Vaccination coverage was 70.0% among children aged 6 months to 13 years and 81.6% among adults aged 65 years and older. The TTE analysis showed that VE against severe outcomes ranged from 63.7% to 74.6%, whereas VE against mortality ranged from 52.2% to 81.1%, depending on the age group. The ITS method demonstrated that protection against hospitalization (VE 41.8%) persisted for up to 2 months after vaccination, whereas protection against mortality (VE 38.1%) persisted for up to 6 months. Overall, influenza vaccination was estimated to have prevented 143,868 influenza cases, including outpatient and inpatient cases, as well as 3,506 deaths. CONCLUSIONS: The findings presented in this annual report provide scientific evidence for optimizing national influenza prevention and response strategies and advancing immunization policy.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Influenza vaccination program with national immunization coverage
- Population
- Children aged 6 months to 13 years and adults aged 65 years and older in South Korea
Key finding
Vaccine effectiveness against severe outcomes ranged from 63.7% to 74.6% depending on age group
Ryu et al. · PubMed (US National Library of Medicine) · 15 Jun 2026